Newsroom

Sorted by: Latest

-

Samenvatting: GENESIS Pharma kondigt een nieuw partnerschap met Otsuka Pharmaceutical Europe Ltd. aan voor het commercialiseren van donidalorsen voor erfelijk angio-oedeem in Centraal- en Oost-Europa

ATHENE, Griekenland--(BUSINESS WIRE)--  AANKONDIGING ALLEEN VOOR EUROPESE MEDISCHE EN FARMACEUTISCHE VAKMEDIA EN EUROPESE FINANCIËLE MEDIA GENESIS Pharma, een regionaal biofarmaceutisch bedrijf dat zich op de commercialisering van innovatieve geneesmiddelen in Centraal- en Oost-Europa richt, kondigt een exclusieve overeenkomst aan voor donidalorsen met Otsuka Pharmaceutical Europe Ltd. (OPEL), de Europese tak van het wereldwijde gezondheidszorgbedrijf Otsuka Pharmaceutical Co., Ltd. In overeens...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Global Equity Income UCITS ETF 12.12.2025 FGBL.LN IE00BYTH6121   78,796.00 USD   6,770,072.77   85.919  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Max Buffer UCITS ETF - September 12.12.2025 MSEP.LN IE0009DRFET8 150,002.00 USD 4,037,126.79 26.914  ...
-

Riassunto: GENESIS Pharma annuncia una nuova partnership con Otsuka Pharmaceutical Europe Ltd. relativa alla commercializzazione di donidalorsen contro l'angioedema ereditario nell'Europa centrale e orientale

ATENE, Grecia--(BUSINESS WIRE)--  ANNUNCIO RISERVATO AI SOLI MEDIA EUROPEI DEL SETTORE MEDICO E FARMACEUTICO E AI SOLI MEDIA EUROPEI DEL SETTORE FINANZIARIO GENESIS Pharma, società biofarmaceutica regionale specializzata nella commercializzazione di farmaci innovativi nell'Europa centrale e orientale, annuncia la sottoscrizione di un accordo esclusivo con Otsuka Pharmaceutical Europe Ltd. (OPEL), l'attività europea della società globale Otsuka Pharmaceutical Co., Ltd. attiva nel settore delle c...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Eurozone AlphaDEX UCITS ETF 12.12.2025 FEUD IE00BF2FL590  366,243.00 EUR  18,238,181.80   49.798  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Rising Dividend Achievers UCITS ETF 12.12.2025 RDVY LN IE000K5F6EL4 525,002.00 USD 11,643,663.34 22.178  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest Nasdaq-100 Moderate Buffer UCITS ETF - June 12.12.2025 QJUN.LN IE000HFBJ0U0 3,400,002.00 USD 72,824,275.80 21.419  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust United Kingdom AlphaDEX UCITS ETF 12.12.2025 FKUD IE00BD9N0445  118,031.00 GBP   3,193,332.35   27.055  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust United Kingdom AlphaDEX UCITS ETF 12.12.2025 FKU IE00B8X9NZ57  209,100.00 GBP   8,060,343.08   38.548  ...
-

Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  Ap27 FORM 8.3 IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION (a) Full name of discloser Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nominee or vehicle companies is insufficient. For...